6885 Stock Overview
A clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BRIM Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$31.20 |
| 52 Week High | NT$50.20 |
| 52 Week Low | NT$24.60 |
| Beta | 1.22 |
| 1 Month Change | -25.54% |
| 3 Month Change | -31.35% |
| 1 Year Change | 5.94% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 22.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6885 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -17.0% | -2.6% | -2.1% |
| 1Y | 5.9% | -0.8% | 25.6% |
Return vs Industry: 6885 exceeded the TW Biotechs industry which returned -0.8% over the past year.
Return vs Market: 6885 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 6885 volatility | |
|---|---|
| 6885 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6885's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6885's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Wenqi Xu | www.brimbiotech.com |
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company’s lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis.
BRIM Biotechnology, Inc. Fundamentals Summary
| 6885 fundamental statistics | |
|---|---|
| Market cap | NT$3.61b |
| Earnings (TTM) | -NT$532.84m |
| Revenue (TTM) | NT$156.00k |
Over9,999x
P/S Ratio-6.8x
P/E RatioIs 6885 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6885 income statement (TTM) | |
|---|---|
| Revenue | NT$156.00k |
| Cost of Revenue | NT$60.00k |
| Gross Profit | NT$96.00k |
| Other Expenses | NT$532.94m |
| Earnings | -NT$532.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.60 |
| Gross Margin | 61.54% |
| Net Profit Margin | -341,564.10% |
| Debt/Equity Ratio | 0% |
How did 6885 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BRIM Biotechnology, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|